ARCTURUS THERAPEUTICS HOLDINGS INC. Expense Breakdown
No Expense Breakdown for ARCT on this site yet.
- 2026-06-30: Payroll and Benefits $8.73M; LUNAR-CF, Net $2.59M; Lunar-Otc $1.87M; Facilities and Equipment $1.85M.
- 2025-06-30: Payroll and Benefits $10.61M; LUNAR-CF, Net $4.63M; Lunar-Otc $2.90M; Facilities and Equipment $2.54M.
Source checked: the stored Expense Breakdown page for ARCT.
Expenses by product
Research and development: each quarter (3 month)
| Quarter end | Payroll and Benefits | LUNAR-CF, Net | Lunar-Otc | Facilities and Equipment | Discovery Technologies | Biomedical Advanced Research and Development Authority | Others |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | $8.73M | $2.59M | $1.87M | $1.85M | $1.34M | $642.00K | Lunar-Covid $391.00K Early-Stage Programs $92.00K |
| 2025-06-30 | $10.61M | $4.63M | $2.90M | $2.54M | $2.44M | $2.46M | Lunar-Covid $3.83M Early-Stage Programs $167.00K |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| Turn Therapeutics Inc. (TTRX) | United States | $0.397B | -25.68 |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |